Preparation and Quality Control of 111In-Plerixafor for Chemokine Receptor CXCR4

Author(s): Ayuob Aghanejad, Amir R. Jalilian, Fatemeh Bolourinovin, Alireza Mirzaee, Khosrou Abdi, Mostafa Erfani, Davood Beiki, Stephan Maus, Ali Khalaj

Journal Name: Recent Patents and Topics on Imaging (Discontinued)
Formerly: Recent Patents on Medical Imaging

Volume 5 , Issue 1 , 2015

Abstract:

Developing CXCR4 receptor imaging agents is of great importance for oncological imaging. In this work, N, N´-[1, 4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane was labeled using high purity [111In]InCl3 in 30- 60 min at 60°C in acetate buffer with acceptable yield and radiochemical purity (>97% ITLC, >95% HPLC, specific activity: 120-200 GBq/mmol). Radiolabeled complex of AMD-3100 ([111In]-AMD3100) showed good stability at room temperature and physiologic conditions in human serum for 24 h. Log P for the complex was determined (-1.18) to be consistent with a water soluble/ionic complex.

The biodistribution of the radiolabeled complex of plerixafor in vital organs of rats was determined up to 48 h demonstrating kidneys as the major route of excretion. Considering lungs, spleen and liver as the CXCR4 rich target organs, the best target:non target ratios (for spleen:blood, lung:blood and liver:blood) were obtained 24 h post injection (5.11, 2.08 and 10.63 respectively).

Keywords: AMD3100, biodistribution, CXCR4, In-111, plerixafor, radiolabeling.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 1
Year: 2015
Page: [26 - 30]
Pages: 5
DOI: 10.2174/2451827105666150903003608

Article Metrics

PDF: 16